We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+23.66%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.11B
AUM Growth
+$195M
Cap. Flow
+$57.8M
Cap. Flow %
5.19%
Top 10 Hldgs %
48.19%
Holding
72
New
18
Increased
12
Reduced
16
Closed
18

Top Buys

1
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.7M
2
ENDP
Endo International plc
ENDP
+$46.9M
3
ALR
Alere Inc
ALR
+$29.1M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$27.8M
5
BIIB icon
Biogen
BIIB
+$21.5M

Top Sells

1
RAD
Rite Aid Corporation
RAD
+$45.4M
2
CELG
Celgene Corp
CELG
+$38.3M
3
GILD icon
Gilead Sciences
GILD
+$34.7M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
5
AZN icon
AstraZeneca
AZN
+$18.2M

Sector Composition

1 Healthcare 81.12%
2 Financials 2.03%
3 Technology 1.63%
4 Communication Services 1.57%
5 Consumer Staples 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WOOF
26
DELISTED
VCA Inc.
WOOF
$16.9M 1.52%
+307,804
New +$16.1M
TRIV
27
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$16.7M 1.5%
1,588,623
-166,945
-10% -$1.72M
PRQR icon
28
ProQR Therapeutics
PRQR
$231M
$16.4M 1.48%
751,171
– –
HNT
29
DELISTED
HEALTH NET INC
HNT
$16.4M 1.47%
270,358
-38,687
-13% -$2.18M
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$16M 1.43%
668,671
-322,139
-33% -$7.22M
GMED icon
31
Globus Medical
GMED
$10.8B
$15.4M 1.39%
611,731
– –
CLDX icon
32
Celldex Therapeutics
CLDX
$2.75B
$15.2M 1.37%
36,467
+34,727
+1,996% +$12.4M
ARAY icon
33
Accuray
ARAY
$30.7M
$14.1M 1.27%
1,515,475
-20,000
-1% -$159K
ABUS icon
34
Arbutus Biopharma
ABUS
$932M
$12.2M 1.1%
+700,000
New +$14.3M
KYTH
35
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$11.3M 1.01%
+225,062
New +$9.45M
ATRA icon
36
Atara Biotherapeutics
ATRA
$73.7M
$11M 0.99%
10,608
+37
+0.4% +$24.5K
NSTG
37
DELISTED
NanoString Technologies, Inc.
NSTG
$11M 0.99%
1,077,642
-188,896
-15% -$2.32M
NVTA
38
DELISTED
Invitae Corporation
NVTA
$10.9M 0.98%
+785,131
New +$14.5M
GWPH
39
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$10.9M 0.97%
+119,114
New +$9.67M
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$9.45M 0.85%
+99,613
New +$7.03M
BLCM
41
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$9.28M 0.83%
44,522
-41,559
-48% -$10.1M
NUVA
42
DELISTED
NuVasive, Inc.
NUVA
$8.51M 0.76%
185,137
-173,542
-48% -$8.06M
CERS icon
43
Cerus
CERS
$649M
$6.87M 0.62%
+1,647,727
New +$8.44M
OPCH icon
44
Option Care Health
OPCH
$3.44B
$6.11M 0.55%
+344,550
New +$7.52M
FLXN
45
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.27M 0.38%
189,624
-125,520
-40% -$2.91M
AKAO
46
DELISTED
Achaogen Inc
AKAO
$3.89M 0.35%
398,340
-335,613
-46% -$3.78M
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$2.79M 0.25%
+78,972
New +$2.7M
CARM
48
DELISTED
Carisma Therapeutics
CARM
$2.14M 0.19%
12,000
– –
IHF icon
49
iShares US Healthcare Providers ETF
IHF
$1.2B
$1.14M 0.1%
42,995
+30,495
+244% +$761K
PPH icon
50
VanEck Pharmaceutical ETF
PPH
$971M
$457K 0.04%
6,500
– –
1
2
3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2015 Portfolio in Review

As of Q1 2015, Redmile Group held 72 positions worth $1.11B, up 21% from $918M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group deployed $57.8M of net new capital in Q1 2015, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Teva Pharmaceuticals: 853,973 shares worth $53.2M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was RECEPTOS INC COM STK (DE), an estimated $19.4M trimmed.

  • Redmile Group's largest Q1 2015 buy was Teva Pharmaceuticals: 853,973 shares worth $53.2M.
  • Redmile Group added most to Biogen in Q1 2015, an estimated $21.5M increase.
  • Redmile Group's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $19.4M.
  • Redmile Group fully exited Rite Aid Corporation in Q1 2015, selling an estimated $45.4M.
  • Redmile Group's ten largest holdings make up 48% of its $1.11B portfolio in Q1 2015.
  • Redmile Group opened 18 new positions and closed 18 in Q1 2015.
  • Redmile Group's portfolio value rose 21% quarter-over-quarter to $1.11B.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.